Financial Data and Key Metrics Changes - As of December 31, 2025, the company reported cash and investments of $301.8 million, indicating a strong financial position to support ongoing clinical programs [24] - The funds expended in 2025 were primarily directed towards the advancement of the HCV Phase 3 program and discovery efforts for HEV treatment [24] - R&D expenses increased in 2025 compared to 2024, driven by external spending on the HCV Phase 3 clinical development [25] Business Line Data and Key Metrics Changes - The global Phase 3 HCV program is on track, with enrollment completed for the North American trial, C-BEYOND, involving over 880 patients [6] - The company anticipates top-line results for C-BEYOND by mid-year and for C-FORWARD by year-end [6][27] - The HEV program has been initiated with AT-587 as the lead product candidate, with plans to start a first-in-human study mid-year [6][27] Market Data and Key Metrics Changes - The incidence of new chronic Hepatitis C infections in the U.S. has increased to approximately 4 million, with only 85,000 patients treated annually [8] - The market opportunity for chronic HEV treatment is estimated to be between $750 million and $1 billion per year, addressing a significant unmet need [20] Company Strategy and Development Direction - The company aims to deliver top-line Phase 3 results for HCV treatments that feature high efficacy, short treatment duration, and low risk of drug-drug interactions [27] - The HEV program represents a strategic expansion of the antiviral pipeline, targeting a vulnerable patient population with no approved treatments available [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving enrollment targets for both C-BEYOND and C-FORWARD trials, indicating a robust clinical development strategy [30] - The company is focused on maintaining financial discipline while advancing its HCV and HEV product candidates, projecting a cash runway extending through 2027 [25][26] Other Important Information - The company returned $25 million to stockholders through a share repurchase program in 2025, reflecting a commitment to drive value for stockholders [24] - The commercial package for HCV will include a blister card for convenience and adherence, with a simple 4-week dosing regimen [17] Q&A Session Summary Question: Does achieving enrollment targets for the cirrhotic population for C-BEYOND increase confidence in C-FORWARD? - Management confirmed that they are on track to achieve overall targets for both trials, with cirrhotic enrollment not being an issue [30] Question: Can you discuss the commercial landscape and pricing evolution for HCV treatments? - Management indicated that the specialty market for DAA is well understood, with stable pricing trends and positive interest from payers regarding the new regimen [34][35] Question: How does the primary endpoint analysis for C-BEYOND affect the potential market uptake? - Management noted that the modified intent-to-treat analysis allows for flexibility in dosing, and the positive profile of the regimen is expected to resonate well with prescribers [39][40]

Financial Data and Key Metrics Changes - Fourth quarter revenues were $13.2 million, representing a 60% increase year-over-year, while full-year revenues were $45.2 million, a 53% increase compared to the previous year [5][21] - Gross margin for the fourth quarter improved to 87% from 85% in the prior year, driven by better manufacturing efficiency [21] - Net operating loss for the quarter was $3.3 million, down from $7.6 million in the prior year, reflecting increased revenue and margin contribution [22] - Adjusted EBITDA loss for the quarter was approximately $950,000, an improvement from a loss of $5.7 million in the prior year [22] Business Line Data and Key Metrics Changes - Revenue from the TriNav system for the year was $45 million, a 53% increase compared to the previous year, primarily driven by increased sales in liver-directed therapies [23] - Research and development expenses decreased by $2.7 million for the year, mainly due to the closeout of clinical trial expenses related to nelitolimod [24] - Sales and marketing expenses increased by $2.9 million for the year, attributed to higher performance-related compensation due to increased sales [24] Market Data and Key Metrics Changes - The total addressable market for liver embolization procedures is approximately $480 million, while the broader embolization market represents a $2.3 billion opportunity [13][14] - The introduction of a new CMS HCPCS code expanded coverage for simulation or mapping procedures using TriNav, effectively doubling the reimbursable use of the technology [14][15] Company Strategy and Development Direction - The primary strategic priority is to expand sales and commercial infrastructure, with plans to double the commercial footprint and enhance clinical studies to validate the PEDD platform [7][9] - The company aims to launch TriNav Advance in the first half of 2026, which is expected to facilitate selective therapy delivery to small distal vessels [13] - The strategy includes conducting foundational studies to prove the superiority of the technology in liver embolization, which is expected to drive long-term penetration in the market [55] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance of $60 million to $62 million for 2026, with growth weighted towards the second half of the year [9][19] - The company noted strong physician engagement and interest in the PEDD platform, indicating a positive outlook for future demand [10] - Management emphasized the importance of investing in commercial infrastructure and clinical evidence to support long-term growth [7][20] Other Important Information - The company raised $46 million in gross proceeds through a public offering, which was oversubscribed and supported by experienced healthcare investors [6][26] - The company is focused on executing near-term milestones, including launching TriNav Advance and publishing clinical data across various indications [19][20] Q&A Session Summary Question: Contribution from liver versus non-liver growth in 2026 - Management indicated that liver will still be the majority of revenue in 2026, with expectations for meaningful progress in non-liver applications tied to data releases later in the year [28][29] Question: Balancing growth cadence and EBITDA pathway - Management stated that specific timing or guidance on cash flow breakeven or adjusted EBITDA breakeven is not being provided at this time, as investments in commercial expansion are ongoing [30] Question: Details on the sales organization structure after investments - Management confirmed that the commercial organization will be significantly expanded, including adding a layer of management to improve sales opportunities [34][35] Question: Growth expectations for mapping and simulation - Management expressed confidence in growth from mapping and simulation, particularly with the introduction of new products like TriNav XP and TriNav Advance [40][41] Question: Use patterns for the TriNav product portfolio - Management noted varied use patterns among physicians, with some preferring specific products while others seek access to the full portfolio for clinical flexibility [48][52] Question: Long-term opportunities for TriNav in liver versus non-liver - Management highlighted that liver will remain a significant component of sales, but there are substantial growth opportunities in non-liver applications, particularly in thyroid artery embolization [54][56]

Financial Data and Key Metrics Changes - Omada Health achieved a 53% revenue growth for the full year 2025, reaching $260 million, with Q4 revenue growing 58% year-over-year to $76 million [4][29] - The total number of members increased to 886,000, a 55% increase compared to 2024, with 55,000 net new members added in Q4 alone [4][17] - The company achieved its first quarter of positive GAAP net income in Q4, reporting $5 million, and delivered positive full-year adjusted EBITDA of $6 million [4][34] Business Line Data and Key Metrics Changes - Revenue from the weight health program grew more than 50%, while revenue from diabetes and hypertension programs grew at rates of 45% or more year-over-year [27][69] - The GLP-1 Care Track saw significant adoption, with over 150,000 members supported on GLP-1s, and members on average achieved greater weight loss compared to published real-world evidence [10][11] Market Data and Key Metrics Changes - Estimated covered lives grew by more than 5 million, ending the year with over 25 million estimated eligible lives [18] - The company noted strong performance across multiple channels, including a successful launch of a large new channel partner [17] Company Strategy and Development Direction - Omada Health is focused on expanding its multi-condition platform, which includes weight health, diabetes, hypertension, and cholesterol management, to provide integrated care solutions [8][24] - The company aims to leverage AI to enhance member support and operational efficiency, embedding AI throughout its services [12][66] - The strategy includes maintaining a balance between growth and profitability, targeting long-term adjusted EBITDA margins of over 20% [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with momentum and a clear plan, highlighting the strong market demand for chronic care solutions and AI-driven innovation [4][5] - The company anticipates 2026 revenue in the range of $312 million to $322 million, reflecting a 22% growth over 2025 [36][37] Other Important Information - Omada Health's GAAP gross margin improved to 71% in Q4, up from 67% in the prior year, and adjusted gross margin reached an all-time high of 73% [30][31] - The company ended 2025 with $222 million in cash and cash equivalents, having generated positive operating cash flow for the year [36] Q&A Session Summary Question: Can you clarify the assumptions behind the 2026 guidance? - Management confirmed that the guidance is based on existing business contributions and does not include new opportunities like GLP-1 prescribing or FlexCare, which could provide upside [42][46] Question: How did January and February track in terms of conversions? - Management reported strong performance in closing additional eligible covered lives and improved enrollment rates, indicating positive trends early in 2026 [48] Question: What is the impact of the new GLP-1 FlexCare program on economics? - The FlexCare program allows employers to support employees with structured models for GLP-1 access, which includes compensation for Omada for facilitating connections [53][56] Question: How is Omada leveraging AI to improve operations? - Omada is utilizing AI for member support and operational efficiencies, with a focus on unique data sets that enhance personalized care [65][66] Question: What traction is being seen in hypertension and diabetes programs? - Management noted strong growth in both diabetes and hypertension programs, reflecting the integrated cardiometabolic care approach [68][69]

Financial Data and Key Metrics Changes - For fiscal 2025, the company reported revenue of $560 million, exceeding the high end of guidance, and Adjusted EBITDA of $70 million, landing in the upper half of the range [5][17] - Fourth quarter revenues decreased by 14% to $145 million, with grill revenues down 22% to $61 million, while consumables revenues increased by 16% to $36 million [18][19] - The net loss for the fourth quarter was $17 million, compared to a net loss of $7 million in the same quarter of 2024 [21] Business Line Data and Key Metrics Changes - Grill category revenues declined primarily due to elasticity and unfavorable mix shifts, while consumables, including pellets, remained a source of strength [18][19] - Accessories revenues decreased by 18% to $49 million, pressured by negative sales growth at MEATER [20] Market Data and Key Metrics Changes - The outdoor grilling market has been relatively steady since 2022, reflecting only modest declines, with the company maintaining market share despite a sluggish category backdrop [6][8] - Connected cooks increased by 11% year-over-year during the holiday season, indicating strong consumer engagement [6][37] Company Strategy and Development Direction - The company is focused on Project Gravity, a multi-year initiative aimed at reshaping the business, simplifying operations, and improving profitability [10][12] - The strategy includes exiting lower return revenue streams, optimizing channel strategies, and launching new products at more accessible price points [10][15] Management's Comments on Operating Environment and Future Outlook - Management noted that tariffs had a significant impact on the category, driving volatility in ordering behavior, but they managed to protect profitability through disciplined pricing and cost control [9][17] - For fiscal 2026, the company is guiding revenue of $465 million-$485 million and Adjusted EBITDA of $50 million-$60 million, reflecting a focus on long-term growth despite expected revenue decline [15][27] Other Important Information - The company expects Project Gravity to deliver approximately $64 million-$70 million of total value across both phases, with benefits beginning to materialize in 2025 and continuing into 2026 [12][27] - The company exited fiscal 2025 with cash and cash equivalents of $20 million and total net debt of $384 million, reflecting a decline of $10 million compared to the previous year [22] Q&A Session Summary Question: What is the company's expectation for grill market growth in 2026? - Management indicated that the market has been modestly down in recent years but expects a recovery as consumers begin to replace grills [34][36] Question: What is the expected revenue impact from the DTC exit? - The revenue impact from exiting DTC and other channels is estimated at around $70 million, with margin rate pressure due to tariffs and promotional deleverage [39][40] Question: Can you elaborate on SKU rationalization efforts? - The company aims to streamline its product portfolio to create efficiencies in manufacturing and improve consumer decision-making [43][44] Question: Why is the decremental margin similar to last year despite Project Gravity? - The decremental margin is impacted by a full year of tariffs and promotional funding deleverage, which erodes margins despite cost-saving initiatives [63][64]

Financial Data and Key Metrics Changes - In Q4 2025, adjusted EBITDA increased by $2.2 million or 17.1% to $15.2 million compared to $13 million in Q4 2024 [4] - Q4 revenue was $90.9 million, a 4% decrease from the prior year period, but excluding flight equipment sales, revenue increased by 9.8% [4][5] - For the full year 2025, total revenue was $335.3 million, a decrease of $9.8 million or 2.8% year-over-year, primarily due to fewer flight equipment sales [6] - Full year adjusted EBITDA increased by $12.8 million to $46.1 million, up 38.2% year-over-year [6][19] Business Line Data and Key Metrics Changes - Asset Management revenue in Q4 declined approximately 11.1% year-over-year to $56.9 million due to fewer flight equipment sales, but excluding these sales, revenue increased by 9.1% [15][16] - TechOps revenue in Q4 increased by 10.7% to $34 million, driven by higher sales in aerostructures and landing gear MROs [16] - For the full year, TechOps revenue declined 4.5% to $123.7 million, primarily due to lower on-airport MRO activity, but gross margin improved to 25.6% from 16.6% in the prior year [17] Market Data and Key Metrics Changes - The company ended 2025 with a win rate of 4.8% in feedstock acquisitions, down from 17.2% in Q4 2024, indicating a hyper-competitive market [7] - The company has approximately $364 million of inventory at the start of 2026, with $150 million ready for deployment in the USM channel [27] Company Strategy and Development Direction - The company aims to mitigate earnings volatility by growing more recurring and predictable parts of the business, including expanding USM sales and leasing [11] - Strategic adjustments in MRO facilities have been made to improve profitability, including transitioning contracts to higher rates and focusing on storage and end-of-life fleet activities [9][10] - The company is committed to the success of its Enhanced Flight Vision System, AerAware, and is actively marketing it to both commercial and governmental customers [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving growth in 2026, supported by efficiency initiatives and a strong balance sheet [12] - The company anticipates steady incremental improvements as new revenue streams ramp up and efficiency initiatives continue to gain traction [20] - Management noted that the market for feedstock remains hyper-competitive, and they will remain disciplined in their purchasing strategy [24] Other Important Information - The company received FAA approval to overhaul Boeing 737 MAX and 787 landing gear, expanding its capabilities to support a growing customer base [10] - The company expects that the full capacity potential of its expansion initiatives will exceed previous estimates of approximately $50 million in annualized opportunity [10] Q&A Session Summary Question: What is the goal for material feedstock purchases this year? - Management anticipates a lower level of feedstock purchases this year than last year due to a hyper-competitive market [22][23] Question: How much inventory is available for monetization? - The company has ample inventory to continue growth without needing to buy as much as last year, with $364 million in inventory at the start of 2026 [27][28] Question: How will GTF normalization and AerSafe deadline impact future revenues? - Management does not expect GTF normalization in 2026 and sees opportunities in returning parked aircraft to service, while AerSafe sales are expected to peak this year [29][31][46]

Financial Data and Key Metrics Changes - In Q4 2025, the company reported record revenue of $106.2 million, exceeding Wall Street expectations, with a year-over-year growth of 5.9% and a sequential growth of 1.9% [3][20] - Full year 2025 revenue reached $411.8 million, representing a 17.5% year-over-year growth [3] - Non-GAAP EBITDA for Q4 was $13.7 million, or 12.9% of revenue, which was at the higher end of the guidance range [20][26] - The company faced a negative impact from foreign exchange fluctuations, amounting to approximately $1.5 million year-over-year [20][21] Business Line Data and Key Metrics Changes - AI revenue grew by 9% over Q3 and accounted for 25% of overall revenue in Q4, with full year AI revenue exceeding $90 million, marking a 30% year-over-year growth [4] - The retail vertical contributed 28.7% of total revenues in Q4, with a sequential increase of 5.3% but a year-over-year decline of 6.9% [21] - The TMT vertical accounted for 28.3% of total revenues, showing a strong year-over-year growth of 27.5% [22] - The finance vertical represented 22.9% of revenues, growing 5% year-over-year, driven by demand from fintech and large banks [22] Market Data and Key Metrics Changes - The company noted a significant increase in partner influence revenue, which exceeded 19% of total revenue in 2025 [6] - The company is prioritizing investments in technology, financial services, and manufacturing sectors, where customized AI solutions are in high demand [5] Company Strategy and Development Direction - The company is focusing on AI-first engineering and agentic enterprise transformation, leveraging its engineering capabilities to meet rising client expectations [9][11] - The introduction of platforms like the Merchandising Experience Platform (MXP) and the bitemporal data platform (XDB) is aimed at generating recurring revenue and enhancing client engagement [6][16] - The company is transitioning from time and material-based engagements to outcome-based contracts, which are expected to improve margins [19][69] Management's Comments on Operating Environment and Future Outlook - Management expressed a bullish outlook for 2026, anticipating revenue growth driven by AI-related projects and partnerships [30][75] - The company is aware of the potential challenges in the market but believes that its focus on custom-built solutions will continue to drive demand [48] - Management highlighted the importance of maintaining a conservative approach to revenue guidance while being optimistic about AI adoption trends [75] Other Important Information - The company ended Q4 with a total headcount of 4,961, slightly down from the previous quarter, but with an increase in billable headcount [23] - Cash and cash equivalents totaled $341.1 million at the end of Q4, indicating a stable financial position [29] Q&A Session Summary Question: AI revenue growth and project scale - Management noted that AI projects are moving from small development phases to full-scale implementations, enhancing client confidence in their solutions [34] Question: Custom build preference among enterprises - Management acknowledged a rising demand for custom-built software solutions, driven by reduced development costs and the need for tailored applications [49] Question: Growth outlook for the year - Management indicated that Q1 is typically affected by seasonality, but they remain positive about the full year due to a robust pipeline of AI-related projects [50][75] Question: Margin expansion framework - Management discussed ongoing efforts to improve margins through internal productivity and geographic optimization, with a target of 300 basis points improvement [82]

Financial Data and Key Metrics Changes - In 2025, AudioEye achieved record revenue growth for the 40th consecutive quarter, with adjusted EBITDA growing by approximately 35% to a record $9.1 million, representing a margin of 22% [4][17] - Q4 2025 revenue reached $10.5 million, an 8% increase from Q4 2024, and a 10% annualized increase from Q3 2025 [11] - For the full year 2025, revenue grew 15% to $40.3 million from $35.2 million in 2024 [11] - Net loss in Q4 2025 was $1.1 million or $0.08 per share, compared to a net loss of $1.5 million or $0.12 per share in the same period last year [16] Business Line Data and Key Metrics Changes - The partner and marketplace channel grew 8% year-over-year in Q4 2025, representing approximately 59% of ARR, with full-year revenue increasing 10% to $22.2 million [11][12] - The enterprise channel grew 8% in Q4 2025 and 21% for the full year, reaching $18.1 million, driven by expansion into the EU [12] - Annual recurring revenue (ARR) at the end of Q4 2025 was $40 million, a 9% increase over the previous year [13] Market Data and Key Metrics Changes - The company anticipates that 2026 will see the highest year of digital accessibility lawsuits on record, driven by increased litigation utilizing AI to detect accessibility issues [6] - The EU market is expected to ramp up as enforcement of regulations increases, with significant deals in the pipeline [29] Company Strategy and Development Direction - AudioEye's next-generation platform aims to unify AI detection, expert audits, and custom fixes, providing unmatched transparency and legal protection [6][7] - The company is focusing on accelerating ARR growth while reducing reliance on non-recurring revenue, with guidance for 2026 indicating revenue growth of between $43 million and $44.5 million [9][25] - The company is leveraging proprietary data to enhance its platform and drive future growth opportunities [32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position, citing a unique data advantage and the potential for significant growth in the accessibility market [24][32] - The company expects adjusted EBITDA to grow by at least 30% in 2026, with a run rate of $15 million by year-end [5][9] Other Important Information - The company repurchased approximately $4.6 million worth of shares in 2025, strengthening its balance sheet [17] - As of December 31, 2025, the company had $5.3 million in cash and $6.6 million in available debt facilities [18] Q&A Session Summary Question: Update on platform updates and human involvement in custom fixes - Management indicated that while AI tools are improving, significant human involvement will still be necessary due to the complexity of accessibility issues [20] Question: Revenue guidance for 2026 and factors influencing it - Management noted that the guidance reflects a conservative approach, focusing on ARR growth and reducing non-recurring revenue [23][25] Question: Update on investments in the EU and opportunities - Management confirmed ongoing pipeline development in the EU, with expectations for increased demand as regulatory enforcement ramps up [29] Question: Potential partnerships related to AI - Management highlighted the unique data they possess and the potential for future partnerships, though specific strategies were not disclosed [31] Question: Update on DOJ Title II enforcement - Management confirmed that DOJ requirements are set to go into effect soon, with strong momentum observed from partners [34] Question: Thoughts on gross margin expectations for 2026 - Management expects gross margins to remain consistent, with potential for growth as AI compute costs are managed [35]

Financial Data and Key Metrics Changes - The reported net loss for the full year 2025 is approximately $63.5 million, which is $45 million higher than in 2024, primarily due to non-cash charges linked to rising stock prices and an asset impairment charge [31][38]. - Total revenues for the fourth quarter were approximately $6.6 million, a net increase of $3.7 million compared to the same period in 2024, driven by higher collaboration revenue from Roche [33]. - Total operating expenses for the fourth quarter were $13.2 million, an increase of $5.2 million compared to the same period in 2024 [34]. Business Line Data and Key Metrics Changes - R&D expenses for the fourth quarter were $8.2 million, an increase of $4.8 million compared to the same period in 2024, primarily driven by costs associated with the OpRegen program [34]. - G&A expenses for the fourth quarter were approximately $4.8 million, an increase of $0.4 million compared to the same period in 2024, mainly due to personnel costs [34]. Market Data and Key Metrics Changes - The company has a cash position of $55.8 million as of December 31, 2025, which, along with proceeds from warrant exercises, is expected to support operations into Q2 of 2028 [32]. - The company has approximately $32 million remaining in underlying warrants priced at $0.91 per share, which could be accelerated if Roche or Genentech advance OpRegen into clinical trials [32]. Company Strategy and Development Direction - The company is focused on leveraging its AlloSCOPE platform to develop scalable, cost-effective cell therapies, with a particular emphasis on addressing the challenges of islet cell transplants for diabetes [24][25]. - The company aims to create a pipeline of differentiated cell-based products, applying lessons learned from existing programs to new initiatives [12][24]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of the OpRegen program to drive positive clinical outcomes in dry AMD, supported by the commitment from Roche [40]. - The company is optimistic about the advancements in its manufacturing capabilities and the potential for new partnerships to fund ongoing development [40]. Other Important Information - The company achieved its first milestone under the Roche collaboration, receiving a $5 million payment, which highlights its contributions to the program [16]. - The company is expanding its research initiatives, including a new focus on type one diabetes, which addresses significant challenges in islet cell transplantation [24][25]. Q&A Session Summary Question: Strategic development of various cell types and AlloSCOPE - Management highlighted the importance of generating new assets that can be partnered early to optimize returns on invested capital [44][46]. Question: Rate-limiting steps in islet cell component scaling - Management noted that transitioning from half-liter to larger scales presents challenges, but they are optimistic about the control achieved at smaller scales [47][49]. Question: Visibility on Roche's GALE study delivery methods - Management provided insights into different delivery methods being tested by Roche, emphasizing the surgical optimization nature of the study [50][52]. Question: Timing of functional measures in the OPC1 program - Management clarified that the OPC1 study is primarily a safety and performance study, with functional assessments occurring at specific intervals [60][61]. Question: Capacity for OpRegen in potential phase 3 trials - Management did not provide specific capacity details but indicated that they are prepared for large-scale trials if necessary [78].

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $32.2 million, with adjusted EBITDA of $12 million, exceeding both consensus estimates and internal expectations [3][12] - Full year revenue totaled $109.4 million, with adjusted EBITDA of $24.3 million, demonstrating the strength of the operating model [3][5] - Gross margin increased from 68.1% in Q4 2024 to 74.8% in Q4 2025, attributed to a favorable product mix and channel partner strategy [13][14] - Net income for Q4 2025 was $5 million, or $0.26 per diluted share, compared to a net loss of $0.1 million in Q4 2024 [15] - Cash and short-term investments increased to $23.4 million as of December 31, 2025, from $13.4 million a year earlier [16] Business Line Data and Key Metrics Changes - The average revenue per top 20 pharmaceutical manufacturer declined slightly from $3 million in 2024 to $2.8 million in 2025, primarily due to lower buy-ups and data-related revenue [17] - The net revenue retention rate remained strong at 116%, indicating solid customer retention and growth [17] Market Data and Key Metrics Changes - There is a noted softness in year-to-date contracted revenue numbers compared to the previous year, driven by a market shift away from managed services [4][5] - The company is seeing a broader pause across clients as they adjust to Most-Favored-Nation pricing negotiations, impacting spending behavior [21][22] Company Strategy and Development Direction - The company is focused on transitioning more customers to a subscription-based model to enhance revenue predictability and establish a consistent recurring revenue component [87] - A $10 million share repurchase program has been authorized, reflecting confidence in the long-term value of the business [6] - The company aims to capture additional market share within the pharma industry's multi-billion dollar digital ecosystem, emphasizing its role as a strategic partner [11][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the current market softness is temporary and expects normalization in spending behavior over the coming months [5][21] - The guidance for 2026 has been updated to reflect a more conservative revenue outlook, with expectations of $109 million to $114 million [5][17] - Management believes there is significant opportunity for value creation, particularly in the mid-tier and long-tail life science companies [3][5] Other Important Information - The company has experienced minimal disruption from AI and views it as a potential tailwind, enabling clients to reallocate marketing budgets towards execution rather than content creation [6][28] - The company is uniquely positioned with a comprehensive commercialization platform that integrates advanced patient-finding capabilities [10][11] Q&A Session Summary Question: Are you seeing conservatism only with the companies in MFN negotiations or is it broader? - Management noted a broader pause across all clients as they digest the implications of MFN negotiations, leading to shorter contract durations [21] Question: Are there nuances between DTC and HCP marketing pressures? - Management indicated that both DTC and HCP marketing are experiencing similar pressures from manufacturers [22] Question: Can you elaborate on the gross margin drivers and sustainability? - Management explained that Q4 2025 had a favorable mix of channel partners driving higher margins, but does not expect this level to be sustainable throughout 2026 [23][25] Question: How is AI impacting operations? - Management stated that AI is creating efficiencies and enabling clients to focus more on commercial execution rather than content creation [27][28] Question: What is the current percentage of revenue under contract? - Management indicated that they are running approximately 15%-20% behind last year's contracted revenue numbers due to shorter contract durations [34][36] Question: What is the guidance for managed services in 2026? - Management stated that the guidance includes very little from managed services, as it is considered an episodic solution [40] Question: What strategies are being employed to capture mid-tier and smaller manufacturers? - Management highlighted the ability to supplement the marketing efforts of mid-tier and long-tail clients, filling gaps in their infrastructure [45][46] Question: How will capital be deployed between debt repayment and share buybacks? - Management indicated that they will evaluate opportunities as they arise, with a historical focus on paying down debt with excess cash flow [49] Question: What are the expectations for net revenue retention in 2026? - Management aims for a net revenue retention rate above 100%, indicating a positive outlook for customer retention [50]

Financial Data and Key Metrics Changes - In Q4 2025, revenue totaled $14.3 million, a decrease of $11.9 million or 46% compared to Q4 2024 [22] - Full-year 2025 revenue increased to $86.2 million from $83.8 million in 2024, driven by strong performance in the first half of the year [24] - Gross profit for Q4 2025 was $9.5 million, a decrease of $12.3 million or 56% from Q4 2024 [23] - Full-year 2025 gross margin was 74.5%, down from 85.6% in 2024 [25] - Net loss for Q4 2025 was $594,000 or $0.04 per share, while full-year net loss was $5.1 million, an improvement from $5.8 million in 2024 [24][27] Business Line Data and Key Metrics Changes - Operating expenses for Q4 2025 were $10.7 million, down more than 50% compared to Q4 2024, primarily due to a 60% decrease in marketing expenses [23] - Full-year operating expenses were $70.9 million, down $6.4 million or 8% from 2024 [26] - The company recognized $1.9 million of other income during 2025, contributing to the improved net loss [26] Market Data and Key Metrics Changes - The company entered 2026 with the strongest sales pipeline for IntentKey to date, building upon 83 new clients acquired in 2025 [16] - The company expects strong double-digit growth for each quarter of 2026, driven by a healthy sales pipeline [28] Company Strategy and Development Direction - The company aims to leverage IntentKey's technology for higher-margin growth and to transition towards high-margin, upstream strategic engagements [10] - Four strategic pillars were outlined: refined go-to-market focus, raising IntentKey's industry profile, continuous product innovation, and high-margin growth [10][12][14] - The company is focusing on partnerships to integrate IntentKey as a service and data provider, aiming for exponential growth through integration [11] Management's Comments on Operating Environment and Future Outlook - The management highlighted a challenging operating environment due to increased regulation and consumer privacy concerns, creating a ripe opportunity for disruption in the industry [7] - The company is optimistic about the recovery of its platform products and expects gradual revenue recovery throughout 2026 [28] - Management emphasized the importance of building brand awareness for IntentKey through thought leadership and presence at industry conferences [35] Other Important Information - The company is migrating its data centers to AWS cloud for cost savings and scalability [19] - A new product-specific website for IntentKey will be launched to support sales teams and encourage self-service trials [16] Q&A Session Summary Question: Capital deployment strategy between existing businesses and new data offering - Management indicated that marketing expenses are tied to sales velocity and demand on the platform, with a focus on demand creation for IntentKey [34] Question: Plans to improve awareness of IntentKey - Management plans to raise IntentKey's profile gradually through marketing investments, industry presence, and targeting high-potential verticals [35][36] Question: Revenue expectations and expense management - Management acknowledged that while revenue is expected to be lower than last year, they are carefully managing expenses and have already started paring back costs [39][41] Question: Growth roadmap for IntentKey self-serve product - Management views the self-serve product as a longer-term ambition, with potential for high margins and stickiness once cultivated [45][46] Question: Breakeven revenue target - Management confirmed that breakeven is still targeted at approximately $100 million in revenue, with a sales mix expected to change significantly in 2026 [48] Question: Relationship with Google and contract extensions - Management emphasized the importance of maintaining quality and integrity in their network to uphold relationships with key partners like Google [52]